Skip to main content

Table 1 Effect of one month treatment with aliskiren on plasma glucose, oxidative stress markers, and antioxidant enzymes in STZ-induced diabetes in mice

From: Insight into the hepatoprotective, hypolipidemic, and antidiabetic impacts of aliskiren in streptozotocin-induced diabetic liver disease in mice

Parameter

Group

Blood glucose (mg/dl)

Insulin (μIU/ml)

GSH (mg/dl)

SOD (U/ml)

MDA (nmol/ml)

NO (µmol/µl)

Normal control

105.83 ± 4

67.67 ± 1.5

9.4 ± 0.67

96.17 ± 1.38

25.15 ± 0.27

87.16 ± 2.41

Diabetic control

448.17 ± 66.24a

26.17 ± 0.7a

4.85 ± 0.06a

61.1 ± 0.7a

40.97 ± 0.39a

240 ± 2.11a

Aliskiren

161 ± 15.4a,b

64.17 ± 1.1b

6.59 ± 0.11a,b

100.17 ± 0.57a,b

27.34 ± 0.32

140.67 ± 0.88a,b

  1. Each value represents mean of 8 mice ± SEM. Statistical analysis was carried out using one way analysis of variance (ANOVA) followed by Tukey Kramer multiple comparisons test
  2. aSignificantly different from Normal control at P < 0.05
  3. bSignificantly different from Diabetic control at P < 0.05